Baselga J, Dent SF, Cortés J, et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. ASCO 2018. J Clin Oncol 36, 2018 (suppl; abstr LBA1006).
NFK: zelfs 10 jaar na diagnose kanker nog steeds klachten
feb 2024 | Borstkanker, Leukemie, Lymfoom, Uro-oncologie